Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Condensed Interim Consolidated Statements of Shareholders??? Equity (Unaudited)

v3.22.1
Condensed Interim Consolidated Statements of Shareholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Share Capital [Member]
Contributed Surplus - Warrant Reserve [Member]
Contributed Surplus [Member]
Deficit [Member]
Total
Balance at Dec. 31, 2020 $ 214,148 $ 1,671 $ 9,401 $ (239,029) $ (13,809)
Balance (in Shares) at Dec. 31, 2020 83,185        
Derivative warrants exercised $ 8,000 8,000
Derivative warrants exercised (in Shares) 8,000        
Derivative warrants exercised - fair value adjustment $ 15,722 15,722
January 2021 equity offering, net of issuance costs $ 7,211 3,164 10,375
January 2021 equity offering, net of issuance costs (in Shares) 7,419        
January 2021 equity offering,broker warrants $ (1,384) 1,384
February 2021 equity offering, net of issuance costs $ 15,165 5,928 21,093
February 2021 equity offering, net of issuance costs (in Shares) 9,585        
February 2021 equity offering,broker warrants $ (1,238) 1,238
Equity warrants exercised $ 2,979 (994) 1,985
Equity warrants exercised (in Shares) 1,319        
Equity warrants expired (642) 642
Stock options exercised $ 27 (12) 15
Stock options exercised (in Shares) 20        
Stock-based compensation expense 769 769
Net loss and comprehensive loss (14,794) (14,794)
Balance at Mar. 31, 2021 $ 260,630 11,749 10,800 (253,823) 29,356
Balance (in Shares) at Mar. 31, 2021 109,528        
Balance at Dec. 31, 2021 $ 263,364 11,749 14,067 (253,887) 35,293
Balance (in Shares) at Dec. 31, 2021 111,203        
Stock-based compensation expense 593 593
Net loss and comprehensive loss (9,221) (9,221)
Balance at Mar. 31, 2022 $ 263,364 $ 11,749 $ 14,660 $ (263,108) $ 26,665
Balance (in Shares) at Mar. 31, 2022 111,203